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Abstract Validated outcome measures are essential in
monitoring disease severity. SpeciWcally in dermatology,
which relies heavily on the clinical evaluation of the patient
and not on laboratory values and radiographic tests, out-
come measures help standardize patient care. Validated
cutaneous scoring systems, much like standardized labora-
tory values, facilitate disease management and follow ther-
apeutic response. Several cutaneous autoimmune
dermatoses, speciWcally cutaneous lupus erythematosus
(CLE), dermatomyositis (DM), and pemphigus vulgaris
(PV), lack such outcome measures. As a result, evaluation
of disease severity and patients’ response to therapy over
time is less reliable. Ultimately, patient care is compro-
mised. These diseases, which are often chronic and relaps-
ing and remitting, are also often refractory to treatment.
Without outcome measures, new therapies cannot be sys-
tematically assessed in these diseases. Clinical trials that
are completed without standardized outcome measures pro-
duce less reliable results. Therefore, the development of
validated outcome measures in these autoimmune dermato-
ses is critical. However, the process of developing these
tools is as important, if not more so, than their availability.
This review examines the steps that should be considered
when developing outcome measures, while further examin-
ing their importance in clinical practice and trials. Finally,
this review more closely looks at CLE, DM, and PV and
addresses the recent and ongoing progress that has been
made in the development of their outcome measures.
Introduction
Validated and responsive outcome measures in dermatol-
ogy are essential to optimal patient care. Objectively moni-
toring disease severity over time is required to ensure
treatment eYcacy. Within the Weld of dermatology, such
measures exist for the more common diseases, such as the
psoriasis activity and severity index (PASI) [11, 37] and the
severity scoring of atopic dermatitis (SCORAD) [18]. In
2000, a review identiWed 13 distinct outcome measures for
atopic dermatitis, including the six-area, six-sign atopic
dermatitis severity score (SASSAD) and the Eczema area
and severity index (EASI) [7]. Additional scores include
the Vitiligo disease activity score (VIDA) [21], as well as
severity scoring systems for acne [9] and rosacea [23].
However, the autoimmune dermatoses, such as cutaneous
lupus erythematosus (CLE), dermatomyositis (DM), and
pemphigus vulgaris (PV), which are far less common, lack
such measures. In general, these diseases wax and wane
and can be refractory to treatment. Both active disease and
damage from burnt out disease can cause signiWcant patient
morbidity. Monitoring response to therapy becomes subjec-
tive and unreliable in the absence of such validated out-
come measures. Drug trials require systematic monitoring
of changes in disease severity. It is impossible to perform
reliable trials and compare outcomes between trials without
validated outcome measures. Scoring systems for these and
other autoimmune dermatoses must be developed in order
E. Gaines · V. P. Werth
Department of Dermatology, University of Pennsylvania, 
Philadelphia, PA, USA
V. P. Werth
Philadelphia V.A, Philadelphia, PA, USA
V. P. Werth (&)
Rhodes Pavilion, 3600 Spruce Street, 
Philadelphia, PA 19104, USA
e-mail: werth@mail.med.upenn.edu123
4 Arch Dermatol Res (2008) 300:3–9to monitor drug eYcacy and establish the need for new
therapies.
Usefulness of validated scoring systems
The ability to objectively measure disease severity in any
Weld is imperative to the practice of evidence based medi-
cine. Validated scoring systems may be generated and
used for a group of diseases, or may be developed for indi-
vidual diseases. In most instances in dermatology, a dis-
ease speciWc outcome measure is more beneWcial since
inherent subtleties within diseases are important to disease
severity. The ability to monitor disease severity over time
and response to treatment is essential to eVective patient
care.
Scoring systems, in general, are useful for cost contain-
ment with the elimination of ineVective interventions and
evaluation of quality of care diVerences across diVerent
providers. Furthermore, the results of any clinical study are
only as good as their endpoints [36]. Uniformly used scor-
ing systems make it possible to compare results of clinical
trials. Without the availability of globally agreed upon out-
comes measures, there is less systematic analysis of drug
eYcacy making it diYcult to justify the use of such drug in
the clinical setting. This holds true for not only new thera-
pies, but also for new indications of currently available
therapies.
Development of scoring systems
The FDA has set guidelines for measuring clinical
response: measure activity, disease-induced damage,
response as determined by the patient, and health-related
quality-of-life [10]. The development of usable outcome
measures requires the collaboration of researchers, clini-
cians and patients to determine what elements of any dis-
ease should be measured and how. Parameters that
constitute disease activity must be clearly deWned. These
parameters must also be sensitive to detect improvement in
disease severity over time. As a whole, the tool itself must
be easy to use. In many cases it is not necessary to capture
all elements of disease severity, as certain parameters may
not be sensitive or speciWc over time. Feasibility of use in a
busy clinical setting must be considered when developing
these measures.
Once tools are developed they need to be validated. If
the tools are going to be used by multiple subspecialists
(i.e. dermatologists and rheumatologists), then they should
be validated by both groups. Singer et al. [29] deWne sev-
eral desirable features of scoring systems. Ideally, clinical
outcome measures should be credible (face validity), com-
prehensive (content validity), sensitive (discriminant validity),
accurate (criterion validity), feasible, and should make bio-
logical sense (construct validity). In this way, a scoring sys-
tem would take into consideration not only what the
patients deem most important, but also what the clinicians
deem to be most clinically relevant.
A valid outcome measure is one that measures what it is
supposed to be measuring. However, validity is not by itself
enough. Scoring systems must also be reliable. Reliability
is the consistency of a set of measurements, or the repeat-
ability of measurements. Williams et al. [36] points out that
there should be reliability within an observer and between
observers. There should also be internal consistency (of
items within a scale), sensitivity to change, and acceptabil-
ity (in terms of time, resources, and costs needed to com-
plete the measure). Finally, validated and reliable tools
should be used in conjunction with and compared to other
less speciWc measures of disease severity, such as analog
physician and patient global skin health scores, as well as
pain, itch and fatigue scales [13].
The development of scoring systems should occur over
time with many collaborators willing to continually revise
and reWne the tool until it is comprehensive without being
burdensome. Finlay [12] recommends that scoring systems
have the following qualities: it must be simple enough to
use in busy clinical setting, include both objective physi-
cian scores and subjective patient scores but also clearly
separate these scores. Parameters used should be unambig-
uous in their meaning and amenable to change as needed.
These parameters should also be able to detect change in
disease severity over time. Finlay also speciWcally points
out that site involvement, and not simply estimated percent
surface area, should be clearly documented.
What is known from dermatologic diseases with widely 
used scoring systems
There are currently a wide array of outcome measures
available for various dermatoses, both disease speciWc
and not. For example, the dermatology index of disease
severity (DIDS) is used for staging the severity of inXam-
matory skin disease [15]. It measures the therapeutic
eVectiveness and magnitude of clinical improvement in
several types of dermatitis, eczema and psoriasis by
assessing body surface area (BSA) and degree of func-
tional limitation. The SCORAD, used in atopic dermatitis,
is another example of a dermatologic outcome measure
that uses BSA to estimate extent of disease involvement.
BSA is often used in outcome measures to estimate extent
of disease involvement.
However, several investigators [7, 8, 26, 33] have found
that measuring BSA does not work, as results are often123
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Furthermore, estimating BSA may underestimate disease
severity in diseases that are often conWned to small areas of
the body. For example, widespread SCLE, which often
resolves without permanent damage, may be more benign
than severe localized discoid LE that is conWned to the
scalp and face and may lead to severe disWgurement [19].
Additionally, improvement in disease that involves only a
small area may be diYcult to measure, limiting its use in
clinical trials.
Another method commonly used to assess extent of dis-
ease involvement is lesion counting. However, Lucky et al.
[2] found that lesion counting was no more reliable than
estimating BSA when studying acne. Furthermore, acne
lesions tend to be fairly distinct. Lesion counting would be
almost impossible in diseases such as SCLE where lesions
tend to coalesce and are often not distinct. Again, with this
method, monitoring disease improvement would be very
diYcult, speciWcally because as larger lesions heal they
may break up into smaller lesions and paradoxically
increase the total lesion count [19].
Scoring systems in autoimmune dermatoses
It is conceptually easy to understand why scoring systems,
in some cases more than one, exist for relatively common
skin diseases. The development of these tools requires an
accessible patient population on which the tool can be
tested, revised, and perfected. Without this patient popula-
tion, the development of scoring systems becomes much
more diYcult.
There is a growing need for validated outcome measures
in autoimmune dermatoses as more clinical trials are being
developed and more therapies are becoming available to be
tested in these diseases. Currently, most scoring systems
being used are disease speciWc, but are developed for spe-
ciWc trials by individual investigators. There needs to be a
collaboration of investigators across dermatology and in
some cases, speciWcally with autoimmune dermatoses,
across subspecialties to create tools that will be used more
broadly. In this way, it becomes possible to compare results
across clinical trials and implement study Wndings into clin-
ical practice.
Cutaneous lupus erythematosus (CLE), DM, and PV are
three examples of autoimmune dermatoses that either lack
or until recently lacked validated outcome measures. They
are also three examples of diYcult to treat diseases that
would easily beneWt from systematic evaluation of newly
available therapies and/or therapies that are currently being
used in other diseases. A closer evaluation of each of these
dermatoses will help illustrate the need for validated scor-
ing systems.
Cutaneous lupus erythematosus and dermatomyositis
Both lupus erythematosus (LE) and DM are complex multi-
system autoimmune disorders, characterized by Xuctuations
in disease severity. Both include a subset of patients who
only have cutaneous involvement. In lupus, while precise
data is not available, it is believed that pure CLE may be
two to three times more prevalent than SLE [32]. In DM,
there is a sub-set of patients with purely cutaneous disease,
known as amyopathic DM, which reportedly occurs in
about 20–40% of DM patients seen by dermatologists [3,
25, 30]. Scoring systems are not only needed to evaluate the
severity of skin involvement but may also provide an alter-
nate way to monitor systemic disease.
In addition, the FDA recently revised their guidelines for
the development of therapeutics in SLE, permitting the
approval of drugs that show eYcacy in one organ system
[6]. Therefore, improvement in the skin alone became suY-
cient to get a drug approved through the FDA. This change
facilitates the development of drug trials and expands the
possible drugs that can be evaluated in cutaneous LE. How-
ever, this change also necessitates the development of a
skin speciWc outcome measure in order to objectively eval-
uate drug eYcacy.
Cutaneous lupus erythematosus
Most epidemiological studies have found that skin involve-
ment is the second most common manifestation of SLE and
is the second most frequent presenting manifestation [31].
Yet the cutaneous manifestations are among the least well-
studied aspect of this multi-system autoimmune illness.
This is in part due to the fact that until recently there was no
tool available to systematically evaluate the severity of skin
disease.
A recent retrospective study identiWed 60 measures of
SLE, but found only 3 to be useful for dermatologists [28].
The SLE Disease Activity Index (SLEDAI) [16] scores the
presence of rash, alopecia, or mucosal ulcers independent
of extent and allots a maximum of 6 points to these Wnd-
ings, with a maximum total score of 105. The lupus activ-
ity criteria count (LACC) [22, 34] scores skin involvement
as one of seven possible organ systems involved and for
the purpose of monitoring severity of skin disease would
be essentially useless. Finally, the SLICC/ACR damage
index for systemic lupus erythematosus [4, 14] gives one
point each for scarring alopecia, extensive scarring other
than the scalp or pulp space, and skin ulceration (excluding
thrombosis) for more than 6 months, accounting for a possible
3 points out of 48. None of these tools for SLE adequately
measure skin involvement for the purposes of clinical
trials.123
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was developed speciWcally to measure disease severity in
CLE, to facilitate drug trials in CLE. First, a consensus as
to what the salient features of CLE are needed, including
what parameters should be measured to deWne activity.
Early on in the design process, it was decided that damage
as well as activity should be measured because in many
cases of CLE, speciWcally the scarring forms such as dis-
coid LE, damage plays a major role in patient morbidity.
This diVerentiation of activity and damage enable the eval-
uation of therapies on both elements of the disease process,
since it is the goal to minimize both activity and permanent
damage. Certain subtypes of CLE may produce permanent
damage and disWgurement, making early intervention with
eVective therapies and prevention of such damage critical
to the long-term well-being of patients. Ultimately, a col-
laborative eVort by the international cutaneous lupus com-
munity generated and promoted the use of a single,
validated outcome measure in CLE [2].
The CLASI, developed by Albrecht and Werth [2], con-
sists of an activity and damage score (Fig. 1). The activity
score takes into account erythema (0–3), scale/hypertrophy
(0–2), mucous membrane lesions (0–1), recent hair loss (0–
1) and non-scarring alopecia (0–3). The damage score rep-
resents dyspigmentation (0–1), scarring/atrophy/panniculi-
tis (0–2), and scarring of the scalp (0–6). Patients are asked
if their dyspigmentation lasts 12 months or longer, in which
case, the dyspigmentation score is doubled. Each of the
above parameters is measured in 13 diVerent anatomical
locations, included speciWcally because they are most often
involved in CLE. The most severe lesion in each area is
measured.
The CLASI has been shown to be a valid and reliable
outcome measure for CLE in three diVerent studies. Con-
tent validity was established by experts in the Weld of der-
matology. Inter-rater reliability correlation coeYcients
were 0.86 for the activity score (95%CI = 0.73–0.99) and
0.92 for the damage score (95%CI = 0.85–1.00). Intra-rater
reliability correlation coeYcients were 0.96
(95%CI = 0.89–1.00) for activity and 0.99 (95%CI = 0.97–
1.00) for damage [1]. The second study [5], a prospective
clinical trial, showed the CLASI to be clinically responsive
to change in disease severity over time. The change in the
CLASI activity score was highly correlated with the change
in the physician’s global assessment of skin health
(r = 0.87, P = 0.005), the change in patient’s global skin
health score (r = 0.85, P = 0.004), and the change in the
patient rated pain score (r = 0.98, P = 0.004). The third
study [17] showed reliability of the CLASI across derma-
tologists and rheumatologists. Clinicians from both subspe-
cialties were able to use the CLASI to assess disease
severity in 14 patients. The dermatologists had an intra-
class coeYcient of r = 0.92 for activity and of r = 0.81 for
damage. The rheumatologists had an intra-class coeYcient
of r = 0.82 and of 0.86 for damage. Intra-rater reliability,
measured with Spearman’s , was 0.94 for activity and 0.97
for damage amongst the dermatologists. Intra-rater reliabil-
ity for the rheumatologists for activity was 0.91 and for
damage was 0.99.
Dermatomyositis
Approximately 60% of patients with adult-onset classical
DM have concurrent presentation of both skin and muscle
involvement, while about 30% present with skin symptoms
weeks to months prior to the onset of muscle involvement.
The Wnal 10% have muscle involvement preceding the
development of skin disease [31]. While there is no one
well-deWned pattern of muscle and skin involvement in
DM, the two are clearly related. Systematic evaluation of
skin involvement is critical to evaluate the eYcacy of ther-
apy of DM.
Development of the cutaneous dermatomyositis area and
severity index (CDASI), for the purpose of clinical trials
and monitoring treatment response, is currently underway.
Information generated from other related studies was used
to help develop the CDASI. SpeciWcally, Rider et al. [28]
developed and validated global assessment tools for juve-
nile idiopathic inXammatory myopathies. They found that
treating physicians deem cutaneous Wndings of these myo-
pathies important indicators of activity, even when associ-
ated with more severe gastrointestinal and muscular
symptoms. In DM, cutaneous symptoms must be evaluated
separately from other systemic symptoms in order to fully
appreciate disease severity, especially in the absence of
muscle symptoms, as with ADM patients.
In addition, calcinosis was found to have the most
impact on damage scores [28]. As in CLE, untreated lesions
may cause permanent morbidity and disability, such as poi-
kiloderma and cutaneous calcinosis. Therefore, the CDASI,
like the CLASI, measures activity and damage separately.
The CDASI has 4 activity (erythema, scale, excoriation,
ulceration) and 2 damage (poikiloderma, calcinosis) mea-
sures for 18 anatomical locations, with scores ranging from
0 to 148. The CDASI also speciWcally measures the hands
(Gottron’s), the periungual area, and alopecia, with use of
diVerent measurements than those used at the other anatom-
ical locations. As with the CLASI, the elements that com-
pose the CDASI activity score are well-established and
likely amenable to change with treatment, although a study
to examine this has yet to be performed.
A recent study examined the reliability and validity of
three tools, the CDASI, the dermatomyositis skin severity
index (DSSI), and the cutaneous assessment tool (CAT)
[27] in measuring disease severity in patients with DM123
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3 tools. Reliability studies demonstrated an intra-class corre-
lation coeYcient (ICC) for test-retest intra-rater reliability of
0.86 for CDASI (95%CI = 0.74–0.98), 0.93 for DSSI
(95%CI = 0.87–0.99), and 0.55 for CAT (95%CI = 0.23–
0.88). Inter-rater reliability studies showed an ICC of 0.83
Fig. 1 Cutaneous LE disease area and severity index (CLASI)
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0.65) for DSSI, and 0.61 (95%CI = 0.42–0.80) for CAT. In
addition, DSSI scores were skewed to the low end of the
scale, suggesting that these scores would be less sensitive
to changes in disease severity over time. The CAT has
poorer inter- and intra-rater reliability than the CDASI, sug-
gesting that the CDASI may be the most useful measure of
cutaneous disease severity in DM.
Pemphigus vulgaris
Pemphigus vulgaris is a rare, potentially life-threatening,
autoimmune blistering disorder. The incidence of PV varies
from 0.5 to 3.2/100,000 people. Flaccid bullae develop on
mucous membranes and skin. Unlike CLE and DM, lesions
in PV are often non-scarring. However, 50–70% of patients
with PV have mucosal involvement, which may cause dys-
phagia and other related morbidity. Immunosuppressive
therapies used in the treatment of PV are the primary cause
of morbidity and mortality in PV patients. Validated out-
come measures are needed for the development and evalua-
tion of new, less toxic therapies for PV.
Three randomized controlled multicenter trials have ever
been reported in PV. One examined the use of dapsone as a
steroid-sparing drug in maintenance phase PV [35], one the
role of adjuvant pulse glucocorticoids in PV [20], a third
examined the role of two immunosuppressives as steroid-
sparing agents in PV [3]. There are currently several ongo-
ing trials in PV, but these trials cannot be compared until an
agreed upon outcome tool is developed to accurately mea-
sure PV disease activity over time. At this point, outcome
measures for PV are being developed on an as needed basis
whenever trials are done. This lack of uniformity greatly
compromises the generalizability of the study results, mak-
ing it diYcult to compare results across trials.
Several outcomes measures for pemphigus have been
developed. Most recently published, the autoimmune bul-
lous skin disorder intensity score (ABSIS) aims to measure
the phenotypical varieties seen across PV, with careful con-
sideration of skin and mucosal involvement as separate
entities with diVerent signiWcance [24]. The ABSIS skin
score measures extent of aVected area and quality of skin
lesions. Extent is assessed by percent of involved BSA and
the “rule of nine”. Quality is deWned as re-epithelialized
lesions (0.5), erosive dry lesions (1.0), or erosive, exudative
lesions with or without a positive Nikolsky’s sign (1.5).
The ABSIS skin score is calculated by multiplying the BSA
by the appropriate quality weighting factor. Oral involve-
ment is assessed separately and with two scores. The Wrst
score assesses extent with 0 for absence of or 1 for presence
of lesions in 11 distinct anatomical locations. The second
score measures severity based on quantitative dysphagia.
A prospective trial is needed to assess the reliability and
validity of the ABSIS.
Another outcome measure for PV, the pemphigus dis-
ease area index (PDAI), has recently been developed as a
part of an international collaborative eVort to create a uni-
versally accepted index of disease severity in PV. Valida-
tion studies took place in August 2007.
A single, validated outcome measure for PV is clearly
needed and is currently being developed. However, collab-
orators must Wrst agree on deWnitions of remission, includ-
ing partial, complete and long-lasting remission.
DeWnitions as to what constitutes a Xare and/or a relapse
must also be deWned. An international eVort to develop
deWnitions of outcomes in pemphigus was initiated in 2005,
after an NIH meeting on pemphigus. This eVort is nearly
completed. Parameters that most accurately measure dis-
ease severity in PV must be deWned. In addition, skin and
mucosal lesions need to be weighted appropriately.
Conclusions
There is a clear need for the development of validated out-
come measures in refractory diseases that are diYcult to
treat. Not only is this imperative for treatment purposes, but
it is also important for systematically evaluating the disease
process. The cutaneous manifestations of LE and DM are
among the least systematically studied largely due to the
fact that validated disease scoring systems did not exist
until recently. Much information about disease progression
and signs of improvement is lacking in the absence of tools
used to monitor disease severity.
First and foremost, collaborative eVorts must be made to
develop tools that best capture the disease process. When
appropriate, collaboration on the development and use of
clinical outcome measures must span across diVerent spe-
cialties, namely dermatology and rheumatology.
There is a need for disease speciWc scoring systems that
are quick, easy to perform, reliable and valid for classifying
disease severity. With the advent of these tools, clinical tri-
als may be carried out in hopes of improving treatments
options.
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